Medicine quality, oncology collaboration and MERS surveillance.
Medicine quality
WHO and INTERPOL strengthen cooperation against falsified medical products
WHO and INTERPOL signed an agreement to coordinate public-health and law-enforcement responses to shared threats. It covers falsified medicines, vaccines and medical devices, alongside biological incidents, organ trafficking and health risks at mass gatherings.
Why it matters: Supports closer cooperation on medicine quality, supply-chain integrity and cross-border threats affecting patients and legitimate pharmaceutical businesses.
WHO and ASCO partner to improve cancer-care quality and trial access
WHO and the American Society of Clinical Oncology formalised a collaboration focused on workforce training, access to clinical trials and cancer-care quality. Planned activities include education tailored to national needs and support for research priorities that reflect local cancer burdens.
Why it matters: Offers a framework for strengthening oncology services and research capacity, particularly where access to specialist care is limited.
WHO reported eight confirmed MERS cases, including one death, in Saudi Arabia between 1 January and 5 October 2026. No links between the cases or secondary infections were identified, and WHO’s regional and global risk assessment remains moderate.
Why it matters: Reinforces the need for respiratory surveillance, travel-history assessment and prompt infection-control measures in healthcare facilities.
Editorial summaries for general information only; not medical advice. Research findings and company announcements should be read in their original context.